Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.
Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.
A long-term follow-up study to obtain safety and efficacy data in subjects who completed
 phase 1/2a clinical trial of NEUROSTEM® (NCT02054208), comparing NEUROSTEM and placebo groups
 for up to 36 months after the initial administration in patients suffering from Alzheimer's
 disease
The subjects will be followed up at 12-month, 24-month, and 36-month (phone call) after the
 initial administration of NEUROSTEM®.
Inclusion Criteria:

 -  Assessment of safety and exploratory treatment efficacy in subjects who were enrolled
 and completed phase 1/2a clinical trial of NEUROSTEM®.

 -  Subjects who have been treated with either NEUROSTEM® or placebo at least 12 months
 ago.

 -  Subjects who voluntarily decided to participate and signed the consent form after
 receiving explanations on the clinical trial (in case it is difficult for the
 participant to sign, the consent of the legal representative)

 Exclusion Criteria:

 -  Subjects who were not enrolled in phase 1/2a clinical trial of Neurostem® for
 assessing safety and exploratory treatment efficacy

 -  Other subjects, excluding those listed above, who were deemed unsuitable by the PI